drugset / Trial / NCT05054842
Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Retagliptin phosphate tablet is a DPP IV inhibitor durg，study number is HR-SP2086-304. The primary purpose of the study is to evaluate the efficacy of the combination of Retagliptin phosphate and metformin compared with placebo and metformin in type 2 diabetes subjects with poor glycemic control treated with metformin for 16 weeks.
Timeline
- Start
- 2021-12-06
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retagliptin | Small molecule | 100 mg | — |
| Background | Metformin | Small molecule | 1500 mg | — |
| Background | Metformin | Small molecule | 2000 mg | — |